[1]宋健,沈舒文,卫昊,等.藤梨根干预肿瘤特定转移途径的蛋白与通路机制研究[J].西部中医药,2026,39(03):103-107.[doi:10.12174/j.issn.2096-9600.2026.03.20]
　SONG Jian,SHEN Shuwen,WEI Hao,et al.Study on the Protein and Pathway Mechanisms of Tengligen in Intervening Specific Tumor Metastasis Pathways[J].Western Journal of Traditional Chinese Medicine,2026,39(03):103-107.[doi:10.12174/j.issn.2096-9600.2026.03.20]
点击复制

藤梨根干预肿瘤特定转移途径的蛋白与通路机制研究()

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
39
期数:
2026年03期
页码:
103-107
栏目:
二次研究
出版日期:
2026-03-15

文章信息/Info

Title:
Study on the Protein and Pathway Mechanisms of Tengligen in Intervening Specific Tumor Metastasis Pathways
作者:
宋健1, 沈舒文1, 卫昊1, 王斌1, 孟凯强1, 白宇雪1, 惠建萍2, 王捷虹2, 赵唯含2, 梁海云3
1.陕西中医药大学，陕西 咸阳 712046
2.陕西中医药大学附属医院，陕西 咸阳 712000
3.宝鸡市人民医院，陕西 宝鸡 721000
Author(s):
SONG Jian1, SHEN Shuwen1, WEI Hao1, WANG Bin1, MENG Kaiqiang1, BAI Yuxue1, HUI Jianping2, WANG Jiehong2, ZHAO Weihan2, LIANG Haiyun3
1.Shaanxi University of Chinese Medicine, Xianyang 712046, China
2.Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang 712000, China
3.Baoji City People’s Hospital, Baoji 721000, China
关键词:
藤梨根; 癌转移; 淋巴转移; 骨转移; AR; 转录
Keywords:
metastasis; lymphatic metastasis; osseous metastasis; AR; transcription
分类号:
R285.5
DOI:
10.12174/j.issn.2096-9600.2026.03.20
文献标志码:
A
摘要:
目的通过整合数据库信息，筛选并明确藤梨根在肿瘤转移各主要途径中起关键作用的蛋白与分子通路，进而比较分析其在各类转移途径中的作用差异，以确定藤梨根主要干预的核心转移途径，从而为后续深入开展藤梨根抗肿瘤转移研究提供理论基础并指明具体方向。 方法通过中药数据分析平台（TCMSP）筛选藤梨根的活性成分及对应靶点，再通过Gene Cards，OMIM和Uniprot三个数据库分别整合淋巴转移和骨转移的相关靶点，将靶点数据导入jvenn做出韦恩图，对韦恩图进行分析，评价两类癌转移途径，优选途径导入String平台得到蛋白质-蛋白质相互作用（protein-protein interaction，PPI），导入Metascape中进行基因本体论（gene ontology，GO）功能富集分析和京都基因与基因组百科全书（Kyoto encyclopedia of genes and genomes，KEGG）通路富集分析，根据KEGG富集得到的通路绘制相关气泡图。整理国内外对藤梨根及其在癌症作用过程中的有效成分、蛋白等在实验中的发现，结合数据库对内容分析整理。整理总结国内关于藤梨根及其复方在临床使用过程中的数据，结合蛋白及分子通路研究为藤梨根及其复方在临床使用提供基础性研究。 结果藤梨根在干预肿瘤转移时，对不同转移途径的效能存在差异。具体而言，其在抑制骨转移方面的效果显著优于淋巴转移。针对淋巴转移途径，藤梨根并非首选治疗药物；相反，在骨转移途径中，藤梨根表现出突出的干预潜力。机制探究显示，这一作用主要与其调控相关转录过程有关。 结论藤梨根对多种癌症的骨转移都是有效的，不仅限于乳腺癌的骨转移。
Abstract:
ObjectiveTo screen and identify the key proteins and molecular pathways through which Tengligen (Radix Actinidiae) exerts its effects on major tumor metastasis pathways by integrating database information, furthermore, to conduct a comparative analysis of its differential effects across various metastatic pathways so as to determine the core metastatic pathways primarily targeted by Tengligen, this provides a theoretical basis and identifies specific directions for subsequent in-depth research on the anti-tumor metastatic effects of Tengligen. MethodsThe active components of Tengligen and their corresponding targets were screened using TCMSP database. Subsequently, targets related to lymphatic metastasis and bone metastasis were integrated from the GeneCards, OMIM, and UniProt databases. These targets were imported into jvenn to generate a Venn diagram. Based on the analysis of the Venn diagram, the two types of tumor metastasis pathways were evaluated, and the preferred pathways were imported into the STRING platform to obtain the protein-protein interaction (PPI) network, further analysis was performed using Metascape for GO functional enrichment analysis and KEGG pathway enrichment analysis. Finally, relevant bubble charts were generated based on the pathways obtained from KEGG enrichment. Experimental findings on Tengligen and its active components and proteins involved in cancer progression, both domestically and internationally, were reviewed. These findings were then integrated and analyzed in conjunction with database resources. Compiling and summarizing clinical data on Tengligen and its compound formulas used in domestic practice, combined with research on related proteins and molecular pathways provide foundational evidence for clinical application of the drug and its formulas. Results Tengligen demonstrates differential efficacy in intervening in tumor metastasis across various metastatic pathways. Specifically, its inhibitory effect on bone metastasis is significantly superior to that on lymphatic metastasis. For the lymphatic metastatic pathway, Tengligen is not the preferred therapeutic agent; conversely, it exhibits prominent intervention potential in bone metastasis. Mechanistic exploration suggests that this effect is primarily associated with its regulation of relevant transcriptional processes. Conclusion Tengligen is effective against bone metastasis in various types of cancer, not limited to breast cancer bone metastasis.

相似文献/References:

[1]宋健,沈舒文,孟凯强,等.基于数据挖掘探究藤梨根成分相似性药物在癌症治疗中的应用[J].西部中医药,2026,39(01):74.[doi:10.12174/j.issn.2096-9600.2026.01.14]
　SONG Jian,SHEN Shuwen,MENG Kaiqiang,et al.Data Mining-based Exploration of Structurally Similar Drugs Derived from Tengli Root for Cancer Treatment[J].Western Journal of Traditional Chinese Medicine,2026,39(03):74.[doi:10.12174/j.issn.2096-9600.2026.01.14]

备注/Memo

备注/Memo:
国家自然科学基金青年基金（81804082）；全国名老中医药专家传承工作室建设项目（国中医药人教发〔2016〕42号）；陕西省科技计划项目（2025SF-YBXM-497）；陕西省教育厅专项科学研究计划项目（18JK0225）；陕西省大学生创新创业训练计划项目（S202110716040）。宋健（1978—），男，博士学位，硕士研究生导师，副教授，副主任医师。研究方向：中医内科学（脾胃病）临床、教学及科研。
更新日期/Last Update: 2026-03-15